TABLE 1.
Total IgG and neutralizing titers (NT) against SARS-CoV-2a
| Anti-S/RBD COVIDAR (PI) | Roche (U/mL) | NT vs ancestral | NT vs gamma | NT vs Delta | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Sample ID | Wks postvaccination |
|||||||||
| 2 | 24 | 2 | 24 | 2 | 24 | 2 | 24 | 2 | 24 | ||
| Non-COVID | 404 | >10 | 1.3 | 89.9 | 29.0 | 16 | 12 | 24 | 1 | 1 | 1 |
| 570 | >10 | 1.7 | 50.6 | 52.0 | 8 | 1 | 12 | 8 | 1 | 1 | |
| 835 | >10 | 1.9 | 137.0 | 116.0 | 16 | 8 | 32 | 8 | 1 | 1 | |
| 891 | >10 | 2.0 | ND | 41.0 | 16 | 8 | 12 | 8 | 1 | 1 | |
| 574 | >10 | 2.1 | 205.6 | 63.0 | 8 | 8 | 48 | 8 | 1 | 1 | |
| 480 | >10 | 2.2 | 120 | 43.0 | 32 | 8 | 8 | 1 | 1 | 1 | |
| 550 | >10 | 2.3 | 218 | 70.0 | 12 | 1 | 1 | 1 | 1 | 1 | |
| 171 | >10 | 2.4 | >250 | 173.0 | 32 | 12 | 12 | 1 | 1 | 1 | |
| 899 | >10 | 3.3 | 137.9 | 87.0 | 12 | 8 | 8 | 1 | 1 | 1 | |
| 140 | >10 | 3.5 | 122.4 | 39.0 | 16 | 1 | 1 | 1 | 1 | 1 | |
| 587 | >10 | 4.1 | 165 | 96.0 | 48 | 16 | 8 | 1 | 1 | 1 | |
| 837 | >10 | 4.8 | >250 | 125.0 | 24 | 8 | 8 | 1 | 1 | 1 | |
| 367 | >10 | 5.3 | >250 | 159.0 | 64 | 16 | 12 | 1 | 1 | 1 | |
| 426 | >10 | 5.8 | >250 | 243.0 | 96 | 24 | 8 | 1 | 1 | 1 | |
| 930 | >10 | 6.8 | >250 | 163.0 | 48 | 24 | 24 | 8 | 1 | 1 | |
| 775 | >10 | 7.0 | 200.0 | 107.0 | 12 | 8 | 1 | 1 | 1 | 1 | |
| 485 | >10 | 7.5 | 196.0 | 244.0 | 24 | 32 | 8 | 16 | 1 | 8 | |
| 346 | >10 | 8.1 | >250 | >250 | 96 | 32 | 12 | 12 | 8 | 8 | |
| 327 | >10 | 9.1 | >250 | >250 | 192 | 96 | 16 | 24 | 12 | 16 | |
| 579 | >10 | 9.7 | >250 | >250 | 96 | 24 | 16 | 8 | 8 | 1 | |
| 908 | >10 | >10 | 144.0 | >250 | 24 | 192 | 8 | 128 | 1 | 24 | |
| 890 | >10 | >10 | >250 | >250 | 24 | 768 | 1 | 192 | 1 | 256 | |
| 961 | >10 | >10 | 185.0 | 242.0 | 64 | 64 | 10 | 8 | 1 | 1 | |
| 794 | >10 | >10 | 116.0 | >250 | 48 | 64 | 12 | 8 | 1 | 8 | |
| 783 | >10 | >10 | >250 | >250 | 256 | 192 | 32 | 16 | 12 | 8 | |
| 744 | >10 | >10 | 182.0 | >250 | 96 | 96 | 24 | 12 | 1 | 8 | |
| 638 | >10 | >10 | >250 | >250 | 192 | 48 | 32 | 16 | 1 | 1 | |
| 663 | >10 | >10 | >250 | >250 | 768 | 512 | 192 | 96 | 32 | 48 | |
| 675 | >10 | >10 | >250 | >250 | 512 | 256 | 64 | 48 | 32 | 16 | |
| 971 | >10 | >10 | ND | >250 | 128 | 96 | 24 | 16 | 1 | 8 | |
| 348 | >10 | >10 | >250 | >250 | 512 | 48 | 24 | 24 | 12 | 1 | |
| COVID-PreV | 395 | 4.2 | 1.8 | 87.0 | 63.0 | 24 | 8 | 1 | 1 | 1 | 1 |
| 652 | >10 | 3.9 | 71.0 | 103.0 | 16 | 20 | 8 | 1 | 1 | 1 | |
| 833 | >10 | 4.5 | >250 | 142.0 | 192 | 48 | 24 | 8 | 1 | 1 | |
| 284 | >10 | 6.3 | >250 | >250 | 256 | 256 | 96 | 32 | 24 | 10 | |
| 895 | >10 | 6.4 | >250 | >250 | 384 | 96 | 32 | 16 | 1 | 1 | |
| 475 | >10 | 6.8 | >250 | 192.0 | 96 | 32 | 12 | 8 | 1 | 1 | |
| 677 | >10 | >10 | >250 | >250 | 768 | 192 | 96 | 64 | 32 | 8 | |
| 278 | >10 | >10 | >250 | >250 | 768 | 192 | 32 | 20 | 32 | 12 | |
| 669 | >10 | >10 | >250 | >250 | 1024 | 384 | 128 | 160 | 128 | 64 | |
| COVID-PostV | 478 | >10 | 3.8 | >250 | >250 | 512 | 512 | 192 | 96 | 256 | 96 |
| 40 | >10 | >10 | 177.0 | >250 | 160 | 768 | 12 | 128 | 1 | 24 | |
| 561 | >10 | >10 | >250 | >250 | 384 | 192 | 96 | 24 | 48 | 16 | |
| 838 | >10 | >10 | >250 | >250 | 192 | 192 | 8 | 24 | 8 | 24 | |
| 549 | >10 | >10 | 236.0 | >250 | 32 | 192 | 1 | 128 | 1 | 128 | |
| 398 | >10 | >10 | >250 | >250 | 16 | 384 | 8 | 128 | 1 | 128 | |
| 377 | >10 | >10 | >250 | ND | 24 | 384 | 12 | 384 | 1 | 384 | |
| 82 | >10 | >10 | >250 | >250 | 32 | 1024 | 8 | 384 | 1 | 384 | |
| 927 | >10 | >10 | 156.0 | >250 | 16 | 512 | 8 | 512 | 1 | 512 | |
a
Forty-nine individuals with paired samples at 2 and 24 weeks post second dose of Sputnik V were analyzed for Anti-S/RBD and neutralizing antibodies. Cohort was differentiated into individuals (i) Non-COVID (n= 31); (ii) COVID-PreV (n = 9); and (iii) COVID-PostV (n = 9). Anti-S/RBD IgG tested with COVIDAR (IP), Anti-S IgG tested with Roche (U/mL), and neutralizing titers (NT) against ancestral SARS-CoV-2, Gamma and Delta, are shown. Samples with NT below 8 were set at 1. ND, not determined.